Searching for just a few words should be enough to get started. If you need to make more complex queries, use the tips below to guide you.
Article type: Research Article
Authors: Saft, Carstena; 1; * | von Hein, Sarah Mariaa; 1 | Lücke, Thomasb | Thiels, Charlotteb | Peball, Marinac | Djamshidian, Atbinc | Heim, Beatricec | Seppi, Klausc; *
Affiliations: [a] Department of Neurology, Huntington Centre NRW, Ruhr-University Bochum, St. Josef-Hospital, Bochum, Germany | [b] Department of Neuropaediatrics, University Children’s Hospital, Ruhr University, Bochum, Germany | [c] Department of Neurology, Medical University Innsbruck, Innsbruck, Austria
Correspondence: [*] Correspondence to: Carsten Saft, Department of Neurology, Huntington Centre NRW, St. Josef-Hospital, Gudrunstr. 56, 44791, Bochum, Germany. Tel.: +49 234 509 6405; E-mail: carsten.saft@ruhr-uni-bochum.de and Klaus Seppi, Department of Neurology, Medical University Innsbruck, A-6020 Innsbruck, Austria. Tel.: +43 512 504 81498; E-mail: Klaus.seppi@tirol-kliniken.at.
Note: [1] These authors contributed equally to this work.
Abstract: Background:Motor symptoms in Huntington’s disease (HD) are heterogeneous with dystonia being described as a symptom with a very high prevalence not only in juvenile cases. Objective:Treatment options for dystonia are limited. Cannabinoids have been described as a potential treatment for patients with dystonia of a different origin. Here, we present early onset HD patients with a marked improvement of motor symptoms mainly due to alleviation of dystonia due to treatment with cannabinoids. In addition we review the current literature concerning the use of cannabinoids in HD. Method:The Unified Huntington’s Disease Rating Scale (UHDRS) motor score, including a chorea and dystonia subscore, was conducted before and after the start of cannabinoids in seven patients without any other changes in medication. Results:The UHDRS motor score and the dystonia subscore (±SD) improved from 70.9 (25.5) to 60.6 (26.9) with a mean change of 10.3 [95% CI 6.0–14.6] and from 12.3 (4.0) to 8.0 (3.6) with a mean change of 4.3 [95% CI 2.3–6.3], respectively (both p = 0.018). Conclusion:Improvement of motor symptoms, mainly dystonia, led to several relevant improvements from a global clinical perspective such as improvement of care, gait and fine motor skills and weight gain. Moreover, we observed changes in behavior with less irritability and apathy, as well as less hypersalivation in some cases.
Keywords: Cannabinoid, dystonia, chorea, Huntington’s, Huntington, sativex, nabilone, dronabinol
DOI: 10.3233/JHD-170283
Journal: Journal of Huntington's Disease, vol. 7, no. 2, pp. 167-173, 2018
IOS Press, Inc.
6751 Tepper Drive
Clifton, VA 20124
USA
Tel: +1 703 830 6300
Fax: +1 703 830 2300
sales@iospress.com
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
IOS Press
Nieuwe Hemweg 6B
1013 BG Amsterdam
The Netherlands
Tel: +31 20 688 3355
Fax: +31 20 687 0091
info@iospress.nl
For editorial issues, permissions, book requests, submissions and proceedings, contact the Amsterdam office info@iospress.nl
Inspirees International (China Office)
Ciyunsi Beili 207(CapitaLand), Bld 1, 7-901
100025, Beijing
China
Free service line: 400 661 8717
Fax: +86 10 8446 7947
china@iospress.cn
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
如果您在出版方面需要帮助或有任何建, 件至: editorial@iospress.nl